Citation Information :
Khan FY, Rasoul F. Rifampicin-isoniazid induced fatal fulminant hepatitis during treatment of latent tuberculosis: A case report and literature review. Indian J Crit Care Med 2010; 14 (2):97-100.
A 42-year-old Indian man received 450 mg rifampicin (RIF) and 150 mg isoniazid (INH) daily after being diagnosed of a latent tuberculosis infection. Baseline serum aminotransferase and total bilirubin levels were within normal limits. On day 31 of treatment, the patient experienced epigastric discomfort and general malaise and one week later he developed nausea and episodic vomiting. The patient missed his first scheduled clinic appointment and he continued taking RIF-INH despite his symptoms. He visited the tuberculosis clinic on day 47 of treatment where he was found to be jaundiced and his liver enzymes were elevated. RIF-INH was stopped and the patient was admitted to our hospital as a case of RIF-INH induced hepatitis. On the 7th day of hospitalization, the patient developed consciousness disturbance with flapping tremor and high ammonia level. The patient was diagnosed with fulminant hepatic failure and transferred immediately to the medical intensive care unit, where he died 4 days later.
Khan FY. Clinical pattern of tuberculous adenitis in Qatar: experience with 35 patients. Scand J Infect Dis 2009;41:128-34.
Centers for Disease Control and Prevention (CDC); American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221-47.
Centers for Disease Control and Prevention (CDC); American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:735-9.
Khan K, Muennig P, Behta M, Zivin JG. Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med 2002;347:1850-9.
Sterling TR, Bethel J, Goldberg S, Weinfurter P, Yun L, Horsburgh CR, et al. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med 2006;173:927-31.
Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibl Tuberc 1970;26:28-106.
Hsu KH. Isoniazid in prevention and treatment of tuberculosis: a 20-year study of the effectiveness in children. JAMA 1974;229:528-33.
Nuermberger E, Bishai WR, Grosset JH. Latent tuberculosis infection. Semin Respir Crit Care Med 2004;25:317-36.
Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 1982;60:555-64.
Moulding T. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 2000;4:485-6.
Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, et al. Improved Adherence and Less Toxicity with Rifampin vs Isoniazid for Treatment of Latent Tuberculosis. Arch Intern Med 2006;166:1863-70.
Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali H, et al. Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis Infection. Ann Intern Med 2008;149:689-97.
Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002;137:640-7.
Centers for Disease Control and Prevention (CDC). Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations: United States, 2001. MMWR Morb Mortal Wkly Rep 2001;50:733-5.
Centers for Disease Control and Prevention (CDC); American Thoracic Society. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection–United States, 2003. MMWR Morb Mortal Wkly Rep 2003;52:735-9.
Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. Joint Tuberculosis Committee of the British Thoracic Society. Thorax 2000;55:887-901
Spyridis NP, Spyridis PG, Gelesme A, Sypsa V, Valianatou M, Metsou F, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007;45:715-22.
Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005;40:670-6.
Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. Chest 1991;99:465-71.
Timbrell JA, Park BK, Harland SJ. A study of the effects of rifampicin on isoniazid metabolism in human volunteer subjects. Hum Toxicol 1985;4:279-85.
Pande JN, Singh SP, Khilnani GC, Khilnani S, Tandon RK. Risk factors for hepatotoxicity from antituberculous drugs: a case control study. Thorax 1996;51:132-6.
Gangadharam PR. Isoniazid, rifampicin, and hepatotoxicity. Am Rev Respir Dis 1986;133:963-5.
Singh J, Arora A, Garg PK, Thakur VS, Pande JN, Tandon RK. Antituberculosis treatment induced hepatotoxicity: role of predictive factors. Postgrad Med J 1995;71:359-62.
Grφnhagen-Riska C, Hellstrom PE, Frφseth B. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Respir Dis 1978;118:461-6.
Wu JC, Lee SD, Yeh PF, Chan CY, Wang YJ, Huang YS, et al. Isoniazid-rifampin induced hepatitis in hepatitis B carriers. Gastroenterology 1990;98:502-4.
Moitinho E, Salmerσn JM, Mas A, Bruguera M, Rodιs J. Severe hepatotoxicity of tuberculostatic agents. Gastroenterol Hepatol 1996;19:448-51.
Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection–New York and Georgia, 2000. Can Commun Dis Rep 2001;27:114-6.
Yew WW. Therapeutic drug monitoring in anti-tuberculosis chemotherapy. Ther Drug Monit 1998;20:469-72.
Attri S, Rana SV, Vaiphei K, Sodhi CP, Katyal R, Goel RC, et al. Isoniazid and rifampicin-induced oxidative hepatic injury–protection by N acetylcysteine. Hum Exp Toxicol 2000;19:517-22.
Richards VE, Chau B, White MR, McQueen CA. Hepatic gene expression and lipid homeostasis in C57BL/6 mice exposed to hydrazine or acetylhydrazine. Toxicol Sci 2004;82:318-32.
Rothfield NF, Bierer WF, Garfield JW. Isoniazid induction of antinuclear antibodies. Ann Intern Med 1978;88:650-2.
Graber CD, Jebaily J, Galphin RL, Doering E. Light chain proteinuria and humoral immunoincompetence in tuberculous patients treated with rifampin. Am Rev Respir Dis 1973;107:713-7.
Gupta S, Grieco MH, Siegel I. Suppression of T-lymphocyte rosettes by rifampin. Ann Intern Med 1975;82:484-8.
Askgaard DS, Wilcke T, Dψssing M. Hepatotoxicity caused by the combined action of isoniazid and rifampicin. Thorax 1995;50:213-4.
Yue J, Peng RX, Yang J, Kong R, Liu J. CYP2E1 mediated isoniazid-induced hepatotoxicity in rats. Acta Pharmacol Sin 2004;25:699-704.
Chowdhury A, Santra A, Bhattacharjee K, Ghatak S, Saha DR, Dhali GK. Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice. J Hepatol 2006;45:117-26.
Roy B, Chowdhury A, Kundu S, Santra A, Dey B, Chakraborty M, et al. Increased risk of anti-tuberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 ′null′ mutation. J Gastroenterol Hepatol 2001;16:1033-7.
Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of Clinical and Immunogenetic Risk Factors in the Development of Hepatotoxicity during Antituberculosis Treatment. Am J Respir Crit Care Med 2002;166:916-9.
Karthikeyan S. Isoniazid and rifampicin treatment on phospholipids and their subfractions in liver tissue of rabbits. Drug Chem Toxicol 2005;28:273-80.
Schreiber J, Zissel G, Greinert U, Schlaak M, Mόller-Quernheim J. Lymphocyte transformation test for the evaluation of adverse effects of antituberculous drugs. Eur J Med Res 1999;4:67-71.
Li B, Wang Z, Fang JJ, Xu CY, Chen WX. Evaluation of prognostic markers in severe drug-induced liver disease. World J Gastroenterol 2007;13:628-32.